Conduct comprehensive administration of company currently active in research and development of spiny lobster culture in Monaco. Actively position the company as a leader in providing organically grown live spiny lobsters. Build strategic business relationships, secure fundraising for research and develop dynamic marketing initiatives.

DORPHAN S.A., a limited company under Swiss legal jurisdiction, whose objective is the development of treatments for rare and orphan genetic diseases.

Sr. Procurement Manager in charge of all Research (Life Sciences) Procurement activities at R&D.Tasks include management and supervision of Procurement Research category team, development and execution of sourcing strategies, expertly advising and guiding the process to the best-fit approach, tactics and tools (e.g. RFP/RFI/RFQ), negotiation and contract management process, Supplier Relationship Management (SRM), compliance to Principles & Policies (P&Ps).Selected Achievements• Negotiated and supervised the setting-up of a substantial amount contracts including licensing and collaborations Agreements with companies, Clinical Research Organizations (CROs) and Institutions worldwide. Fields covered include computational biology, scientific and clinical trials assessment for Modified Risks Tobacco Products (MRTPs).

Launched this biotech firm to continue the pioneering development of EDI200, an orphan drug product for XLHED that was underway at APOXIS, S.A. during a five-year tenure in the dual role of Director of Business Development and Project Leader. XLHED is a rare genetic disease affecting hundreds of newborns each year worldwide. Life-threatening condition includes the absence of sweat glands for body temperature regulation, and the abnormal development and/or lack of hair and teeth. R&D efforts at Apoxis were interrupted due to a corporate acquisition.Selected Achievements• Developed an innovative business plan to include outsourced laboratory research.• Negotiated and secured exclusive in-licensing rights for EDI200.• Raised $22M in Series A financing in June 2009 from venture capital firms in the U.S. and Europe.• Managed corporate business operations.• CTI-label (certificate of quality delivered by the Swiss government) granted to the company end of 2009.

Recruited as a business consultant for this company specialized in the development of therapeutics for Alzheimer’s disease to rewrite its business plan for a Series Round-C financing and to manage business development activities. (This mission was conducted while establishing and conducting financing round for Edimer Biotech).Selected Achievements• The company raised $40M by close of 2008

Managed business development initiatives; cultivated strategic partnerships with companies as well as government, medical, scientific and academic communities; and coordinated public relation activities such as press release / business report writing, brand messaging, creation of marketing materials and website design.In 2005, appointed as Project Leader of a pre-clinical program in the field of rare diseases. Team-oriented, jointly worked with Heads of various departments to ensure that objectives were accomplished. Established a strong and long-lasting network with governmental agencies, patient associations, institutions and bio/pharmaceutical companies worldwide. Selected Achievements• Organized and directed the successful research and development of EDI200, a pre-clinical stage drug.• Strengthened negotiations with both pharmaceutical and biotech firms; solidified critical contract commitments and licensing agreements for technologies and products. • Served as a presenter and Company representative at major biotech and pharmaceutical events worldwide.• Managed award submissions / secured Swiss Technology (2004) and Red Herring (2005) awards.